Abstract
In a single-blind, placebo-controlled study the acute and chronic antianginal effects of three slow-release (SR) new formulations of isosorbide dinitrate (ISDN 60, 80, 100 mg) have been comparatively evaluated in a group of aged affected by chronic stable effort-induced angina. Compared to placebo, overall the active dose paritetically improved the effort tolerance up to 24 h after the first assumption. In the time course of the trial (2 and 4 weeks) the resting hemodynamic changes induced by the first dose were partially blunted without affecting the exercise related-parameters. Also if plasma levels of ISDN and of its metabolites did not correlate to the degree of physical improvement, the peak increase in effort tolerance was observed under 100 mg treatment. Mild to moderate transient headache was experienced by 50% of actively treated and by 20% of placebo treated patients and no other serious adverse effects have been noted. One may conclude that ISDN in slow-release formulations of 60-100 mg isan effective, safe and well tolerated medication in the management of angina in the aged.
References
Mar 1, 1978·Chest·G LeeA N DeMaria
Jul 1, 1986·International Journal of Cardiology·J C Cowan
Apr 15, 1986·The American Journal of Cardiology·N S KhurmiE B Raftery
Dec 1, 1986·Giornale italiano di cardiologia·S Scardi
Nov 1, 1987·The American Journal of Medicine·S SilberK Theisen
Jul 1, 1985·American Heart Journal·J S Schroeder
Jul 1, 1985·American Heart Journal·C V Leier
Dec 27, 1985·The American Journal of Cardiology·J R Weber
Jan 1, 1985·European Heart Journal·C R Conti
Apr 1, 1972·The American Journal of Cardiology·T SweatmanK E Cohn
Jul 1, 1983·Journal of the American College of Cardiology·J J DalalJ O Parker
Oct 1, 1984·Circulation·P L McHenryJ J Jordan
Sep 1, 1980·Circulation·U ThadaniJ O Parker